181. Integrating clinical profiles and microRNAs to uncover molecular mechanisms in treatment-resistant schizophrenia
Abstract Background Treatment-resistant schizophrenia (TRS), defined as the persistence of symptoms despite adequate antipsychotic treatment, remains frequently underrecognized, with clozapine, the gold standard, introduced only after an average delay of 4–9 years. In this study, we aimed to identify which Positive and...